English (UK)
中文版INOVOTION 
In vivo efficacy evaluation in oncology
Mr. Philippe Fornies
Head of Business Development
Regulaxis
Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.
Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.
Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.
Dr. Matthieu CHAREYRE
Chief Business Development Officer - Global Pharmaceutical Operations
Regulaxis SAS
Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.
Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.
Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.
Mr. Raffaello Paolini
R&D Project Manager – East Asian operations development
SYNSIGHT
Our innovative platform and our technologies can be directly applied to protein-protein or protein-RNA interactions. Our bioassay is unique and patented and is able to qualify and quantify these interactions directly in human cell, and also of course the efficacy of small molecule modulators (Hit identification, "in cell IC50" measurement). This assay, easy to setup as medium or high-throughput screening level, is then able to train our AI models which generate new molecules.
We already successfully used our platform to study oncologic and neurodegenerative targets, for our own R&D or for customers. Our platform is able to manage different therapeutic area (oncology, virology, neurology, …), and different targets from your portfolio. We also propose to feed your portfolio and develop screening setup of our platform with exclusivity, with innovative targets like TPD-43, YB-1, alpha-SYN, BCL2, HUR, …
Dr. Cyril Bauvais
CEO
VITANLINK
Within a competitive timeframe, start-ups and small and medium-sized businesses successfully move from seed to post-seed stages, from growth to scaling up to new markets
In partnership with family offices, advisory boutiques, regional accelerators and investment funds
Responsive Web Design powered by 